

Product Data Sheet

RRD-251

Cat. No.: HY-117737A CAS No.: 72214-67-6 Molecular Formula: $C_{g}H_{g}Cl_{g}N_{g}S$ Molecular Weight: 271.59

Target: Raf; Apoptosis

Pathway: MAPK/ERK Pathway; Apoptosis

Storage: 4°C, sealed storage, away from moisture

* In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

SOLVENT & SOLUBILITY

In Vitro

DMSO: 125 mg/mL (460.25 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	3.6820 mL	18.4101 mL	36.8202 mL
	5 mM	0.7364 mL	3.6820 mL	7.3640 mL
	10 mM	0.3682 mL	1.8410 mL	3.6820 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description RRD-251 is an inhibitor of retinoblastoma tumor suppressor protein (Rb)-Raf-1 interaction, with potent anti-proliferative, anti-angiogenic and anti-tumor activities^[1].

Rb-Raf-1 interaction, apoptosis^[1] IC₅₀ & Target

RRD-251 (10-50 μ M; 24 hours) inhibits melanoma growth in-vitro [1]. In Vitro

RRD-251 (50 μM; 2 hours) inhibits Rb-Raf-1 interaction and Rb phosphorylation in non-small cell lung cancer cells^[1].

RRD-251 induces apoptosis (50 μ M; 18 hours) and cell cycle arrest (20-50 μ M; 4 hours) [1].

RRD-251 alters the expression of cell cycle and apoptosis regulatory protein^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1]

Cell Line:	SK-MEL-28 cells , SK-MEL-5 cells, SK-MEL-2 cells
Concentration:	10 μΜ, 20 μΜ, 50 μΜ
Incubation Time:	24 hours

Result:	Inhibited melanoma growth in-vitro.		
Western Blot Analysis ^[1]			
Cell Line:	SK-MEL-28 cells , SK-MEL-5 cells, SK-MEL-2 cells		
Concentration:	50 μΜ		
Incubation Time:	2 hours		
Result:	Showed the depletion of phosphorylated-Rb in RRD-251 treated cells.		
Apoptosis Analysis ^[1]			
Cell Line:	SK-MEL-28 cells , SK-MEL-5 cells, SK-MEL-2 cells		
Concentration:	50 μΜ		
Incubation Time:	18 hours		
Result:	Induced apoptosis.		
Cell Cycle Analysis ^[1]			
Cell Line:	SK-MEL-28 cells , SK-MEL-5 cells		
Concentration:	20 μΜ, 50 μΜ		
Incubation Time:	4 hours		
Result:	Resulted in a dose dependent inhibition of cell cycle progression in SK-MEL-28 and SK-MEL-5 cells, respectively.		
RRD-251 (50 mg/kg; i.p.;	q.o.d; for 14 days) has anti-cancer activities in vivo on melanomas $^{\left[1\right] }.$		
MCE has not independe	ntly confirmed the accuracy of these methods. They are for reference only.		
Animal Model:	8-wk-old female athymic nude mice, with SK-ME-28 xenograft $^{[1]}$		
Dosage:	50 mg/kg		
Administration:	Intraperitoneal administration, qod, for 14 days		

REFERENCES

In Vivo

[1]. Sandeep Singh, et al. Rb-Raf-1 interaction disruptor RRD-251 induces apoptosis in metastatic melanoma cells and synergizes with dacarbazine. Mol Cancer Ther. 2010 Dec; 9(12): 3330–3341.

Inhibits the growth of SK-ME-28 xenograft in nude mice.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Result:

Fax: 609-228-5909

 $\hbox{E-mail: tech@MedChemExpress.com}$

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA